DBV Technologies SA - American (DBVT) AI Stock Analysis

DBV Technologies SA - American

(NASDAQ:DBVT)

Select Model

Rating:49Neutral

Price Target:$10.00▲(10.38% Upside)

Action:reiterated

Date:10/30/26

Overall score reflects weak financial performance driven by ongoing losses and significant cash burn, with moderate offset from a low-debt balance sheet. Earnings-call progress (BLA submission and runway into Q3 2027) supports the outlook but is constrained by regulatory/manufacturing execution risks. Technicals remain broadly bearish with the stock below key longer-term moving averages.

Positive Factors

Regulatory advancementThe completed BLA submission advances VIASKIN toward potential commercialization and represents a concrete regulatory milestone. If the application progresses successfully, DBV could transition from a development-stage company toward recurring product revenue and broader commercial validation.

Negative Factors

No commercial revenueThe absence of recurring commercial revenue leaves DBV dependent on capital markets and future regulatory success to support its cost base. Persistent and widening operating losses also show that current activities are not yet self-funding, increasing execution pressure before commercialization.

DBV Technologies SA - American (DBVT) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $227.02M
Dividend Yield: ―
Average Volume (3M): 369.71K
Price to Earnings (P/E): -3.2
Beta (1Y): 0.20
Revenue Growth: ―
EPS Growth: 42.37%
Country: US
Employees: 125
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase II...

DBV Technologies SA - American Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:-14.93%|Next Earnings Date:Mar 10, 2027

Earnings Call SentimentPositive

The call was predominantly positive, centered on the completed 4-through-7 BLA submission, cash funding into the third quarter of 2027, progress toward commercial readiness, FDA engagement and continued advancement of the toddler program. However, the company still faces significant execution and regulatory dependencies, including Fareva's unresolved Warning Letter remediation, an unscheduled FDA reinspection, pending Priority Review decisions, uncertainty around the toddler BLA process and higher operating expenses.

Positive Updates

BLA Submitted for Children Aged 4 to 7

DBV Technologies submitted its Biologics License Application for VIASKIN Peanut Patch in children aged 4-through-7 years, which management described as the highlight of the third quarter and an important step toward becoming a commercial company.

Negative Updates

Fareva Warning Letter Creates Site-Wide Remediation Challenge

Fareva Amboise received an FDA Warning Letter following a September 2025 inspection of veterinary-product manufacturing. The observations focused on quality-management operations and systems and have site-wide implications at the Amboise facility, requiring ongoing remediation relevant to VIASKIN Peanut Patch manufacturing.

Company Guidance

DBV estimates that its existing cash will fund operations into the third quarter of 2027, expects to submit a toddler BLA in 2027, and included a PAI readiness target date after Fareva expects to have completed remediation, with February 1 shared with the FDA as the date it would be ready for an inspection; the company said it is planning for the best case scenario, which is a tight timeline, with no extra buffer time, and remains comfortable that all that can be managed within the clock of Priority Review. DBV said setting up a new facility takes about 3 years, is looking at a sales force of 50 to 70 people to target 4,500 allergists in the U.S., and said you launch a blockbuster on 18 months of preparation; it will not be providing guidance on first year sales potential.

DBV Technologies SA - American Financial Statement Overview

Summary

Financial profile is weak due to zero/minimal revenue, widening operating losses, and heavy cash burn (TTM free cash flow around -$267M). This is partially offset by a comparatively solid balance sheet with low leverage and a still-meaningful equity cushion, but ongoing losses increase future funding risk.

Income Statement

18Very Negative

Balance Sheet

63Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	15.73M	4.84M	5.71M
Gross Profit	0	0	-6.81M	15.73M	4.84M	-4.68M
EBITDA	-198.17M	-143.86M	-110.99M	-63.27M	-83.47M	-91.16M
Net Income	-207.33M	-146.95M	-113.72M	-72.73M	-96.27M	-97.81M
Balance Sheet
Total Assets	215.40M	233.72M	65.66M	182.99M	246.52M	146.32M
Cash, Cash Equivalents and Short-Term Investments	165.70M	194.17M	32.46M	141.37M	209.19M	77.30M
Total Debt	22.20M	21.68M	7.80M	6.55M	10.03M	10.66M
Total Liabilities	66.70M	64.95M	38.27M	42.80M	52.06M	47.29M
Stockholders Equity	148.60M	168.77M	27.39M	140.19M	194.45M	99.03M
Cash Flow
Free Cash Flow	-267.71M	-121.18M	-106.81M	-80.33M	-56.45M	-109.16M
Operating Cash Flow	-266.98M	-121.18M	-104.47M	-79.65M	-55.70M	-108.24M
Investing Cash Flow	-6.84M	-1.37M	-757.00K	-808.00K	-100.00K	-433.00K
Financing Cash Flow	384.97M	276.18M	587.00K	6.77M	194.10M	274.00K

DBV Technologies SA - American Technical Analysis

Technical Analysis SentimentNegative

Last Price9.06

Price Trends

50DMA11.53Negative

100DMA13.32Negative

200DMA16.95Negative

Market Momentum

MACD-0.40Negative

RSI39.69Neutral

STOCH64.41Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Negative. The current price of 9.06 is below the 20-day moving average (MA) of 9.66, below the 50-day MA of 11.53, and below the 200-day MA of 16.95, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 39.69 is Neutral, neither overbought nor oversold. The STOCH value of 64.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DBVT.

DBV Technologies SA - American Risk Analysis

DBV Technologies SA - American disclosed 78 risk factors in its most recent earnings report. DBV Technologies SA - American reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

DBV Technologies SA - American Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DBVT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	54Neutral	$657.41M	-4.38	-41.33%	―	278712.12%	26.59%
KRRO	54Neutral	$210.80M	-1.43	-114.26%	―	-62.08%	-2.62%
LXEO	52Neutral	$257.76M	-2.73	-41.85%	―	―	64.51%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DBVT	49Neutral	$596.78M	-3.17	-121.83%	―	―	42.37%
LRMR	48Neutral	$256.59M	-1.24	-137.39%	―	―	-27.00%

* Healthcare Sector Average

Performance Comparison

DBVT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DBVT	DBV Technologies S.A. - American Depositary Shares	9.49	-4.76	-33.40%
LRMR	Larimar Therapeutics, Inc.	2.47	-1.41	-36.34%
KRRO	Korro Bio, Inc.	14.31	-22.51	-61.12%
FDMT	4D Molecular Therapeutics, Inc.	11.90	0.68	6.06%
LXEO	Lexeo Therapeutics, Inc.	3.14	-5.90	-65.27%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

DBV Technologies SA - American AI Stock Analysis